Cargando…

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation

Detalles Bibliográficos
Autores principales:	Mann, JF, McKay, PF, Swales, J, Klein, K, Fiserova, A, Cope, A, Shattock, RJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441860/ http://dx.doi.org/10.1186/1742-4690-9-S2-P316

Ejemplares similares

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations
por: Pattani, Aditya, et al.
Publicado: (2012)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
por: Donnelly, L, et al.
Publicado: (2009)

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
por: Morrow, RJ, et al.
Publicado: (2009)

Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
por: Cranage, Martin P., et al.
Publicado: (2011)

Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses
por: Curran, Rhonda M., et al.
Publicado: (2009)

Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms
por: Donnelly, Louise, et al.
Publicado: (2011)

P11-09. Mucosal vaccination with a transferrin-gp140 conjugate via the nasal but not vaginal route elicits robust systemic and vaginal IgG and IgA responses
por: Mann, JF, et al.
Publicado: (2009)

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP(®) DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
por: Edupuganti, Srilatha, et al.
Publicado: (2020)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen()
por: Mann, J.F.S., et al.
Publicado: (2012)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial
por: Gombe, Ben, et al.
Publicado: (2022)

A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
por: Kratochvil, Sven, et al.
Publicado: (2017)

Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2017)

Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice
por: Mann, Jamie F. S., et al.
Publicado: (2013)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2018)

Intradermal Immunization of EBOV VLPs in Guinea Pigs Induces Broader Antibody Responses Against GP Than Intramuscular Injection
por: Liu, Ying, et al.
Publicado: (2020)

P11-06. Intravaginal administration of HIV-1ZM96 gp140 augments systemic and mucosal antibody responses following systemic priming with adjuvanted protein
por: Cranage, M, et al.
Publicado: (2009)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
por: Lewis, DJ, et al.
Publicado: (2009)

Phase I Randomised Clinical Trial of an HIV-1(CN54), Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally
por: Lewis, David J., et al.
Publicado: (2011)

Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
por: McKay, PF, et al.
Publicado: (2012)

Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses
por: Johansson, Daniel X., et al.
Publicado: (2012)

Improving the Repeatability and Efficacy of Intradermal Electroporated Self-Replicating mRNA
por: Huysmans, Hanne, et al.
Publicado: (2019)

P19-29. Determining the optimal protocol for plasmid DNA vaccine delivery by intradermal in vivo electroporation
por: Hallengärd, D, et al.
Publicado: (2009)

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques
por: Todorova, Biliana, et al.
Publicado: (2017)

Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation
por: Generotti, Alison, et al.
Publicado: (2023)

Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice
por: Van Roey, Griet A, et al.
Publicado: (2012)

The Safety and Immunogenicity of GTU(®)MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART
por: Haidari, G., et al.
Publicado: (2019)

Optimised Electroporation for Loading of Extracellular Vesicles with Doxorubicin
por: Lennaárd, Angus J., et al.
Publicado: (2021)

DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques
por: Kulkarni, Viraj, et al.
Publicado: (2014)

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
por: Msafiri, Frank, et al.
Publicado: (2020)

Intramuscular electroporation with the pro-opiomelanocortin gene in rat adjuvant arthritis
por: Chuang, I-Chuan, et al.
Publicado: (2004)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

A “Prime-Pull” Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice
por: Tregoning, John S., et al.
Publicado: (2013)

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines
por: Hallengärd, David, et al.
Publicado: (2012)

Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen
por: Arias, Mauricio A., et al.
Publicado: (2011)

A Meta‐analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events
por: Marra, Fawziah, et al.
Publicado: (2012)

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes
por: Joseph, Sarah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bd3v83el5ki3fme1r0o6lqq2or